These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target. Lin D; Wu J World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101 [TBL] [Abstract][Full Text] [Related]
6. Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile. Facciorusso A; Antonino M; Del Prete V; Amoruso A; Neve V; Barone M Curr Drug Saf; 2015; 10(3):202-7. PubMed ID: 25994808 [TBL] [Abstract][Full Text] [Related]
7. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005 [TBL] [Abstract][Full Text] [Related]
9. Targeting tyrosine kinase receptors in hepatocellular carcinoma. Muntané J; De la Rosa AJ; Docobo F; García-Carbonero R; Padillo FJ Curr Cancer Drug Targets; 2013 Mar; 13(3):300-12. PubMed ID: 23016985 [TBL] [Abstract][Full Text] [Related]
10. [Current status of molecular targeted therapies in hepatocellular carcinoma]. Suh SJ; Yim HJ Korean J Gastroenterol; 2013 Mar; 61(3):136-46. PubMed ID: 23575232 [TBL] [Abstract][Full Text] [Related]
11. Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma. Makarova AS; Lazarevich NL Klin Lab Diagn; 2013 Oct; (10):66-8, 34-7. PubMed ID: 24640100 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Cervello M; McCubrey JA; Cusimano A; Lampiasi N; Azzolina A; Montalto G Oncotarget; 2012 Mar; 3(3):236-60. PubMed ID: 22470194 [TBL] [Abstract][Full Text] [Related]
13. Improved chemotherapy for hepatocellular carcinoma. Cao H; Phan H; Yang LX Anticancer Res; 2012 Apr; 32(4):1379-86. PubMed ID: 22493374 [TBL] [Abstract][Full Text] [Related]
14. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line. Wang W; Xu B; Li Q; Jiang D; Yan S Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394 [TBL] [Abstract][Full Text] [Related]
15. Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma. Sun T; Liu H; Ming L Cell Physiol Biochem; 2017; 44(2):716-727. PubMed ID: 29169150 [TBL] [Abstract][Full Text] [Related]
17. Role of microRNAs in the development of hepatocellular carcinoma and acquired drug resistance. Tricoli L; Niture S; Chimeh U; Kumar D Front Biosci (Landmark Ed); 2019 Jan; 24(3):545-554. PubMed ID: 30468672 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525 [TBL] [Abstract][Full Text] [Related]
20. Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma. Sato K; Mori M Curr Med Chem; 2011; 18(28):4375-88. PubMed ID: 21861817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]